title: Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats.
abstract: Previous clinical and animal studies suggest that selective activators of M(1) and/or M(4) muscarinic acetylcholine receptors (mAChRs) have potential as novel therapeutic agents for treatment of schizophrenia and Alzheimer's disease. However, highly selective centrally penetrant activators of either M(1) or M(4) have not been available, making it impossible to determine the in vivo effects of selective activation of these receptors. We previously identified VU10010 [3-amino-N-(4-chlorobenzyl)-4, 6-dimethylthieno[2,3-b]pyridine-2-carboxamide] as a potent and selective allosteric potentiator of M(4) mAChRs. However, unfavorable physiochemical properties prevented use of this compound for in vivo studies. We now report that chemical optimization of VU10010 has afforded two centrally penetrant analogs, VU0152099 [3-amino-N-(benzo[d][1,3]dioxol-5-ylmethyl)-4,6-dimethylthieno[2,3-b]pyridine carboxamide] and VU0152100 [3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno[2,3-b]pyridine carboxamide], that are potent and selective positive allosteric modulators of M(4). VU0152099 and VU0152100 had no agonist activity but potentiated responses of M(4) to acetylcholine. Both compounds were devoid of activity at other mAChR subtypes or at a panel of other GPCRs. The improved physiochemical properties of VU0152099 and VU0152100 allowed in vivo dosing and evaluation of behavioral effects in rats. Interestingly, these selective allosteric potentiators of M(4) reverse amphetamine-induced hyperlocomotion in rats, a model that is sensitive to known antipsychotic agents and to nonselective mAChR agonists. This is consistent with the hypothesis that M(4) plays an important role in regulating midbrain dopaminergic activity and raises the possibility that positive allosteric modulation of M(4) may mimic some of the antipsychotic-like effects of less selective mAChR agonists.
authors.affiliation: Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-6600, USA.
authors.forename: Ashley E
authors.initials: AE
authors.lastname: Brady
authors.forename: Carrie K
authors.initials: CK
authors.lastname: Jones
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Bridges
authors.forename: J Phillip
authors.initials: JP
authors.lastname: Kennedy
authors.forename: Analisa D
authors.initials: AD
authors.lastname: Thompson
authors.forename: Justin U
authors.initials: JU
authors.lastname: Heiman
authors.forename: Micah L
authors.initials: ML
authors.lastname: Breininger
authors.forename: Patrick R
authors.initials: PR
authors.lastname: Gentry
authors.forename: Huiyong
authors.initials: H
authors.lastname: Yin
authors.forename: Satyawan B
authors.initials: SB
authors.lastname: Jadhav
authors.forename: Jana K
authors.initials: JK
authors.lastname: Shirey
authors.forename: P Jeffrey
authors.initials: PJ
authors.lastname: Conn
authors.forename: Craig W
authors.initials: CW
authors.lastname: Lindsley
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000494:Allosteric Regulation; D000818:Animals; D004298:Dopamine; D008636:Mesencephalon; D009043:Motor Activity / Q000187:drug effects*; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D043588:Receptor, Muscarinic M4 / Q000819:agonists*; D013876:Thiophenes / Q000494:pharmacology*
chemical_list: C579414:3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide; D011725:Pyridines; D043588:Receptor, Muscarinic M4; D013876:Thiophenes; D000109:Acetylcholine; D004298:Dopamine
references.citation: Crit Rev Neurobiol. 1996;10(1):69-99
references.pmid: 8853955
references.citation: J Pharmacol Exp Ther. 2001 Nov;299(2):782-92
references.pmid: 11602695
references.citation: Mol Pharmacol. 2003 Sep;64(3):731-40
references.pmid: 12920211
references.citation: J Pharmacol Exp Ther. 2005 Apr;313(1):199-206
references.pmid: 15608073
references.citation: Arch Neurol. 1997 Apr;54(4):465-73
references.pmid: 9109749
references.citation: Curr Opin Pharmacol. 2006 Feb;6(1):98-102
references.pmid: 16368268
references.citation: J Med Chem. 2004 Nov 18;47(24):5825-8
references.pmid: 15537338
references.citation: Mol Pharmacol. 2006 Aug;70(2):616-26
references.pmid: 16645124
references.citation: Life Sci. 2001 Apr 27;68(22-23):2457-66
references.pmid: 11392613
references.citation: J Physiol. 1998 Jul 15;510 ( Pt 2):421-7
references.pmid: 9705993
references.citation: Am J Psychiatry. 2008 Aug;165(8):1033-9
references.pmid: 18593778
references.citation: Mol Pharmacol. 2008 Apr;73(4):1213-24
references.pmid: 18171729
references.citation: Neuropsychopharmacology. 1988 Sep;1(3):179-86
references.pmid: 3075131
references.citation: Neurochem Res. 2003 Apr;28(3-4):437-42
references.pmid: 12675128
references.citation: Life Sci. 2001 Apr 27;68(22-23):2605-13
references.pmid: 11392633
references.citation: FASEB J. 2004 Sep;18(12):1410-2
references.pmid: 15231726
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13668-73
references.pmid: 14593202
references.citation: Nat Chem Biol. 2008 Jan;4(1):42-50
references.pmid: 18059262
references.citation: J Pharmacol Exp Ther. 2004 May;309(2):568-77
references.pmid: 14747613
references.citation: Neurochem Res. 2006 Apr;31(4):555-61
references.pmid: 16758365
references.citation: Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):163-81
references.pmid: 12769625
references.citation: Eur J Neurosci. 2003 Apr;17(7):1403-10
references.pmid: 12713643
references.citation: Mol Psychiatry. 2007 Mar;12(3):232-46
references.pmid: 17146471
references.citation: Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10483-8
references.pmid: 10468635
references.citation: J Pharmacol Exp Ther. 2006 Jul;318(1):173-85
references.pmid: 16608916
references.citation: Biol Psychiatry. 2007 May 15;61(10):1161-70
references.pmid: 17239354
references.citation: Curr Top Med Chem. 2002 Apr;2(4):353-8
references.pmid: 11966459
references.citation: Trends Neurosci. 2007 Oct;30(10):545-53
references.pmid: 17904652
references.citation: Bioorg Med Chem Lett. 2007 Mar 1;17(5):1386-91
references.pmid: 17210250